Optimized expression of human interleukin-15 in Nicotiana benthamiana and in vitro assessment of its activity on human keratinocytes
Human interleukin-15 (hIL-15) is a cytokine essential for immune modulation with therapeutic applications in cancer and chronic wound healing. Although hIL-15 is commercially available, large-scale production studies remain limited. With promising clinical trial results, demand for hIL-15 is expected to rise. Plant expression systems offer a sustainable, low-cost alternative for rapid biopharmaceutical production. In this study, we optimized hIL-15 expression in <i>Nicotiana benthamiana</i> and assessed its physicochemical properties and biological activity. We fused hIL-15 to the Fc domain of human IgG1 for efficient purification. Through optimization of the pre- and post-infiltration conditions, we achieved transient expression and recovery at 4 dpi, yielding 33.8 µg/g fresh weight. Peptide mapping confirmed 97 % overall sequence coverage of the primary structure. Treatment with plant-produced hIL-15-Fc effectively promoted human keratinocyte HaCaT cell proliferation and migration <i>in vitro</i>. These findings demonstrated the potential of plant-based platforms for producing therapeutic recombinant hIL-15 that support wound healing.
Authors
- Pipob Suwanchaikasem (ORCID: https://orcid.org/0000-0001-7991-6414)
- Kaewta Rattanapisit (ORCID: https://orcid.org/0000-0001-6773-076X)
- Christine Joy I. Bulaon (ORCID: https://orcid.org/0009-0003-6736-4132)
- Waranyoo Phoolcharoen (ORCID: https://orcid.org/0000-0001-5958-7406)
- Iksen Iksen (ORCID: https://orcid.org/0000-0003-0166-4792)
- Varisa Pongrakhananon (ORCID: https://orcid.org/0000-0002-2220-0842)
- Chalatorn Charnsatabut
Institutions
- Chulalongkorn University (TH)
- Bangkok University (TH)
Publication Details
- Journal
- Biotechnology Reports
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1016/j.btre.2025.e00889
- Citations
- 2
- Primary Topic
- Transgenic Plants and Applications
- Type
- article
- Field-Weighted Citation Impact
- 2.47